<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MENESTÂ - estrogens, esterifiedÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<a href="http://"></a><p class="First"><span class="Bold"><span>ESTROGENS</span> INCREASE THE RISK OF 
ENDOMETRIAL CANCER</span></p>
<p>Close clinical surveillance of all women taking estrogens is important. 
Adequate diagnostic measures, including endometrial sampling when indicated, 
should be undertaken to rule out malignancy in all cases of undiagnosed 
persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the 
use of â€œnaturalâ€? estrogens results in a different endometrial risk profile than 
synthetic estrogens at equivalent estrogen doses. (See <span class="Bold"><a href="#section-7">WARNINGS</a></span>, <a href="#section-7.2">Malignant 
neoplasms</a>, <a href="#section-7.2.1">Endometrial cancer</a>.)</p>
<p><span class="Bold">CARDIOVASCULAR AND OTHER RISKS</span></p>
<p>Estrogens with and without progestins should not be used for the prevention 
of cardiovascular disease. (See <span class="Bold"><a href="#section-7">WARNINGS</a></span>, <a href="#section-7.1">Cardiovascular 
disorders</a>.) The Womenâ€™s Health Initiative (WHI) study reported increased 
risks of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary 
emboli, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) 
during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) 
combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (See 
<span class="Bold"><a href="#section-4">CLINICAL PHARMACOLOGY</a></span>, <a href="#section-4.5">Clinical Studies</a>.) The Womenâ€™s Health Initiative Memory 
Study (WHIMS), a substudy of WHI, reported increased risk of developing probable 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of 
treatment with oral conjugated estrogens plus medroxyprogesterone acetate 
relative to placebo. It is unknown whether this finding applies to younger 
postmenopausal women or to women taking estrogen alone therapy. (See <span class="Bold"><a href="#section-4">CLINICAL PHARMACOLOGY</a></span>, <a href="#section-4.5">Clinical Studies</a>.) Other doses of conjugated estrogens 
with medroxyprogesterone acetate, and other combinations and dosage forms of 
estrogens and progestins were not studied in the WHI clinical trials and, in the 
absence of comparable data, these risks should be assumed to be similar. Because 
of these risks, estrogens with or without progestins should be prescribed at the 
lowest effective doses and for the shortest duration consistent with treatment 
goals and risks for the individual woman.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Esterified estrogens is a mixture of the sodium salts of the 
sulfate esters of the estrogenic substances, principally estrone, that are of 
the type excreted by pregnant mares. The content of total esterified estrogens 
is not less than 90 percent and not more than 110 percent of the labeled amount. 
Esterified estrogens contain not less than 75 percent and not more than 85 
percent of sodium estrone sulfate, and not less than 6 percent and not more than 
15 percent of sodium equilin sulfate, in such proportion that the total of these 
two components is not less than 90 percent, all percentages being calculated on 
the basis of the total esterified estrogens content.</p>
<a href="http://"></a><a href="http://"></a>Inactive Ingredients:<p>Ethyl cellulose, fragrances, hydroxypropyl cellulose, 
hypromellose 2910, lactose, magnesium stearate, methylcellulose, polyethylene 
glycol, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, shellac, starch, stearic acid, titanium dioxide, and 
vanillin. Dyes in the form of aluminum lakes are contained in each tablet 
strength as follows: <span class="Underline">0.3 mg Tablet</span><span class="Bold">:</span> FD&amp;C Yellow No. 6, D&amp;C Yellow No. 10. <span class="Underline">0.625 mg Tablet:</span><span class="Bold"></span> FD&amp;C Yellow 
No. 6, D&amp;C Yellow No. 10. <span class="Underline">1.25 mg Tablet:</span> 
FD&amp;C Yellow No. 6, D&amp;C Yellow No. 10, FD&amp;C Blue No. 1.Â <span class="Underline">2.5 mg Tablet:</span> D&amp;C Red No. 30.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous estrogens are largely responsible for the development 
and maintenance of the female reproductive system and secondary sexual 
characteristics. Although circulating estrogens exist in a dynamic equilibrium 
of metabolic interconversions, estradiol is the principal intracellular human 
estrogen and is substantially more potent than its metabolites, estrone and 
estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian 
follicle, which secrets 70 to 500mcg of estradiol daily, depending on the phase 
of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by 
conversion of androstenedione, secreted by the adrenal cortex, to estrone by the 
peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone 
sulfate, are the most abundant circulating estrogens in postmenopausal 
women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive 
tissues. To date, two estrogen receptors have been identified. These vary in 
proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, 
luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a 
negative feedback mechanism. Estrogens act to reduce the elevated levels of 
these hormones seen in postmenopausal women.</p>
<a href="http://"></a><a href="http://"></a>Distribution<p>The distribution of exogenous estrogens is similar to that of 
endogenous estrogens. Estrogens are widely distributed in the body and are 
generally found in higher concentrations in the sex hormone target organs. 
Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> 
(SHBG) and albumin.</p>
<a href="http://"></a><a href="http://"></a>Metabolism<p>Exogenous estrogens are metabolized in the same manner as 
endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of 
metabolic interconversions. These transformations take place mainly in the 
liver. Estradiol is converted reversibly to estrone, and both can be converted 
to estriol, which is the major urinary metabolite. Estrogens also undergo 
enterohepatic recirculation via sulfate and glucuronide conjugation in the 
liver, biliary secretion of conjugates into the intestine, and hydrolysis in the 
gut followed by reabsorption. In postmenopausal women, a significant proportion 
of the circulating estrogens exist as sulfate conjugates, especially estrone 
sulfate, which serves as a circulating reservoir for the formulation of more 
active estrogens.</p>
<a href="http://"></a><a href="http://"></a>Excretion<p>Estradiol, estrone, and estriol are excreted in the urine along 
with glucuronide and sulfate conjugates.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-3"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First">In vitro and in vivo studies have shown that estrogens are 
metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or 
inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 
such as St. Johnâ€™s Wort preparations (Hypericum perforatum), phenobarbital, 
carbamazepine, and rifampin may reduce plasma concentrations of estrogens, 
possibly resulting in a decrease in therapeutic effects and/or changes in the 
<span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, 
clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may 
increase plasma concentrations of estrogens and may result in side effects.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<a href="http://"></a>Womenâ€™s Health Initiative Studies.<p class="First">The Womenâ€™s Health Initiative (WHI) enrolled a total of 27,000 
predominantly healthy postmenopausal women to assess the risks and benefits of 
either the use of oral 0.625 mg conjugated estrogens (CE) per day alone or the 
use of oral 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone 
acetate (MPA) per day compared to placebo in the prevention of certain chronic 
diseases. The primary endpoint was the incidence of coronary heart disease (CHD) 
(nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as 
the primary adverse outcome studies. A â€œglobal indexâ€? included the earliest 
occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), 
endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other 
cause. The study did not evaluate the effects of CE or CE/MPA on menopausal 
symptoms.</p>
<p>The CE/MPA substudy was stopped early because, according to the predefined 
stopping rule, the increased risk of breast cancer and cardiovascular events 
exceeded the specified benefits included in the â€œglobal index.â€? Results of the 
CE/MPA substudy, which included 16,608 women (average age of 63 years, range 50 
to 79; 83.9% White, 6.5% Black, 5.5% Hispanic), after an average follow-up of 
5.2 years are presented in Table 1 below:</p>
<a name="i048c2e54-17f9-4489-8eda-e5e861366367"></a><table border="1" cellpadding="2" cellspacing="1">
<caption><span>Table 1. RELATIVE AND ABSOLUTE RISK SEEN IN THE CE/MPA SUBSTUDY OF 
WHI<span class="Sup">a</span></span></caption>
<col width="134">
<col width="123">
<col width="64">
<col width="65">
<tbody class="Headless">
<tr class="First">
<td>Event<span class="Sup">c</span>
</td>
<td>Relative Risk CE/MPA vs placebo at 5.2 Years (95% 
CI*)</td>
<td>Placebo n=8102</td>
<td>CE/MPA n=8506</td>
</tr>
<tr><td>Absolute Risk per 10,000 Person-years</td></tr>
<tr>
<td>CHD events 
<p class="First">Â Â Â Non-fatal MI </p>
<p>Â Â Â CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </p>
</td>
<td>1.29 (1.02-1.63) 
<p class="First">1.32 (1.02-1.72)</p>
<p>1.18 (0.70-1.97) </p>
</td>
<td>30 
<p class="First">23</p>
<p>6</p>
</td>
<td>37
<p class="First">30</p>
<p>7</p>
</td>
</tr>
<tr>
<td>Invasive breast cancer<span class="Sup">b</span>
</td>
<td>1.26 (1.00-1.59) </td>
<td>30 </td>
<td>38</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </td>
<td>1.41 (1.07-1.85)</td>
<td>21 </td>
<td>29</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> </td>
<td>2.13 (1.39-3.25) </td>
<td>8 </td>
<td>16</td>
</tr>
<tr>
<td>Colorectal cancer </td>
<td>0.63 (0.43-0.92) </td>
<td>16 </td>
<td>10</td>
</tr>
<tr>
<td>Endometrial cancer </td>
<td>0.83 (0.47-1.47) </td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span> </td>
<td>0.66 (0.45-0.98) </td>
<td>15</td>
<td>10</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to causes other than the events above </td>
<td>0.92 (0.74-1.14) </td>
<td>40 </td>
<td>37</td>
</tr>
<tr>
<td>Global Index<span class="Sup">c</span>
</td>
<td>1.15 (1.03-1.28) </td>
<td>151 </td>
<td>170</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">d</span>
</td>
<td>2.07 (1.49-2.87) </td>
<td>13 </td>
<td>26</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">d</span>
</td>
<td>0.66 (0.44-0.98) </td>
<td>15</td>
<td>9</td>
</tr>
<tr class="Last">
<td>Other <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span><span class="Sup">d</span>
</td>
<td>0.77 (0.69-0.86) </td>
<td>170 </td>
<td>131</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> adapted from JAMA, 2002; 288:321-333</p>
<p><span class="Sup">b</span> includes metastatic and non-metastatic breast cancer 
with the exception of in situ breast cancer</p>
<p><span class="Sup">c</span> a subset of the events was combined in a â€œglobal 
indexâ€?, defined as the earliest occurrence of CHD events, invasive breast 
cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, endometrial cancer, colorectal cancer, hip 
<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes</p>
<p><span class="Sup">d</span> not included in Global Index</p>
<p><span class="Sup">*</span> nominal confidence intervals unadjusted for multiple 
looks and multiple comparisons</p>
<p>For those outcomes included in the â€œglobal index,â€? absolute excess risks per 
10,000 women-years in the group treated with CE/MPA were 7 more CHD events, 8 
more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 8 more PEs, and 8 more invasive breast cancers, while absolute 
risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 
fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the â€œglobal 
indexâ€? was 19 per 10,000 women-years. There was no difference between the groups 
in terms of all-cause mortality. (See <span class="Bold"><a href="#section-2">BOXED WARNING</a></span>, <span class="Bold"><a href="#section-7">WARNINGS</a></span>, and <span class="Bold"><a href="#section-8">PRECAUTIONS</a></span>.)</p>
<a href="http://"></a><a href="http://"></a>Womenâ€™s Health Initiative Memory Study<p>The Womenâ€™s Health Initiative Memory Study (WHIMS), a substudy of 
WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age 
and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 
years of age and older) to evaluate the effects of CE/MPA (0.625 mg conjugated 
estrogens plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the estrogen/ progestin 
group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 
women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95% CI, 1.21 to 3.48) 
compared to placebo. Differences between groups became apparent in the first 
year of treatment. It is unknown whether these findings apply to younger 
postmenopausal women. (See <span class="Bold"><a href="#section-2">BOXED 
WARNING</a></span> and <span class="Bold"><a href="#section-7">WARNINGS</a></span>, <a href="#section-7.3"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Menest is indicated in the:</p>
<ol>
<li><p class="First">Treatment of moderate to severe vasomotor symptoms associated 
with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p></li>
<li><p class="First">Treatment of moderate to severe symptoms of vulvar and vaginal 
<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. When prescribing solely for the treatment 
of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be 
considered.</p></li>
<li><p class="First">Female <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p></li>
<li><p class="First">Female castration.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">Primary ovarian failure</span>.</p></li>
<li><p class="First">Breast cancer (for palliation only) in appropriately selected 
women and men with <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</p></li>
<li><p class="First">Prostatic carcinoma - palliative therapy of advanced 
disease.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Menest should not be used in women with any of the following 
conditions:</p>
<ol>
<li><p class="First">Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p></li>
<li><p class="First">Known, suspected, or history of cancer of the breast except in 
appropriately selected patients being treated for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. </p></li>
<li><p class="First">Known or suspected estrogen-dependent neoplasia. </p></li>
<li><p class="First">Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or a history of 
these conditions. </p></li>
<li><p class="First">Active or recent (e.g., within the past year) arterial 
thromboembolic disease (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</p></li>
<li><p class="First">Liver dsyfunction or disease.</p></li>
<li><p class="First">Menest should not be used in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> 
to its ingredients.</p></li>
<li><p class="First">Known or suspected pregnancy. There is no indication for Menest 
in pregnancy. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> 
in children born to women who have used estrogens and progestins from oral 
contraceptives inadvertently during early pregnancy. (See <span class="Bold"><a href="#section-8">PRECAUTIONS</a></span>.)</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><a href="#section-2">BOXED 
WARNINGS</a></span>.</p>
<p>The use of unopposed estrogens in women who have a uterus is associated with 
an increased risk of endometrial cancer.</p>
<a href="http://"></a><a href="http://"></a>1. <span><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></span><p>Estrogen and estrogen/progestin therapy has been associated with 
an increased risk of cardiovascular events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, as well as <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (venous 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> or VTE). Should any of these occur or be suspected, estrogens 
should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 
mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or venous 
<span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> (e.g., personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and 
<span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<a href="http://"></a><a href="http://"></a>a. Coronary heart disease and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span><p>In the Womenâ€™s Health Initiative study (WHI), an increase in the 
number of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> has been observed in women 
receiving CE compared to placebo. These observations are preliminary. (See <span class="Bold"><a href="#section-4">CLINICAL PHARMACACOGY</a></span>, <a href="#section-4.5">Clinical Studies</a>.)</p>
<p>In the CE/MPA substudy of WHI, an increased risk of coronary heart disease 
(CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was 
observed in women receiving CE/MPA compared to women receiving placebo (37 vs 30 
per 10,000 women-years). The increase in risk was observed in year one and 
persisted.</p>
<p>In the same substudy of WHI, an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed in 
women receiving CE/MPA compared to women receiving placebo (29 vs 21 per 10,000 
women-years). The increase in risk was observed after the first year and 
persisted.</p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 
66.7 years) a controlled clinical trial of secondary prevention of 
cardiovascular disease (Heart and Estrogen/Progestin Replacement study; HERS) 
treatment with CE/MPA (0.625mg/2.5mg per day) demonstrated no cardiovascular 
benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not 
reduce the overall rate of CHD events in postmenopausal women with established 
coronary heart disease. There were more CHD events in the CE/MPAtreated group 
than in the placebo group in year 1, but not during the subsequent years. Two 
thousand three hundred and twenty-one women from the original HERS trial agreed 
to participate in an open label extension of HERS, HERS II. Average follow-up in 
HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of 
CHD events were comparable among women in the CE/MPA group and the placebo group 
in HERS, HERS II and overall.</p>
<p>Large doses of estrogen (5 mg conjugated estrogens per day), comparable to 
those used to treat cancer of the prostate and breast, have been shown in a 
large prospective clinical trial in men to increase the risks of nonfatal 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.</p>
<a href="http://"></a><a href="http://"></a>b. <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> (VTE)<p>In the Womenâ€™s Health Initiative study (WHI), an increase in VTE 
has been observed in women receiving CE compared to placebo. These observations 
are preliminary. (See <span class="Bold"><a href="#section-4">CLINICAL 
PHARMACOLOGY</a></span>, <a href="#section-4.5">Clinical Studies</a>.)</p>
<p>In the CE/MPA substudy of WHI, a 2-fold greater rate of VTE, including deep 
<span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, was observed in women receiving CE/MPA 
compared to women receiving placebo. The rate of VTE was 34 per 10,000 
women-years in the CE/MPA group compared to 16 per 10,000 women-years in the 
placebo group. The increase in VTE risk was observed during the first year and 
persisted.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before 
surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or 
during periods of prolonged immobilization.</p>
<a href="http://"></a><a href="http://"></a>2. <span>Malignant neoplasms</span><a href="http://"></a><a href="http://"></a>a. <span>Endometrial cancer</span><p>The use of unopposed estrogens in women with intact uteri has 
been associated with an increased risk of endometrial cancer. The reported 
endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold 
greater than in non-users, and appears dependent on duration of treatment and on 
estrogen dose. Most studies show no significant increased risk associated with 
use of estrogens for less than one year. The greatest risk appears associated 
with prolonged use, with increased risks of 15- to 24-fold for five to ten years 
or more and this risk has been shown to persist for at least 8 to 15 years after 
estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women taking estrogen/progestin combinations is 
important. Adequate diagnostic measures, including endometrial sampling when 
indicated, should be undertaken to rule out malignancy in all cases of 
undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no 
evidence that the use of natural estrogens results in a different endometrial 
risk profile than synthetic estrogens, of equivalent estrogen dose. Adding a 
progestin to estrogen therapy has been shown to reduce the risk of endometrial 
<span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
<a href="http://"></a><a href="http://"></a>b. Breast cancer<p>The use of estrogens and progestins by postmenopausal women has 
been reported to increase the risk of breast cancer. The most important 
randomized clinical trial providing information about this issue is the Womenâ€™s 
Health Initiative (WHI) substudy of CE/MPA (see <span class="Bold"><a href="#section-4">CLINICAL PHARMACOLOGY</a></span>, <a href="#section-4.5">Clinical Studies</a>). The results from observational 
studies are generally consistent with those of the WHI clinical trial and report 
no significant variation in the risk of breast cancer among different estrogens 
or progestins, doses, or routes of administration.</p>
<p>The CE/MPA substudy of WHI reported an increased risk of breast cancer in 
women who took CE/MPA for a mean follow- up of 5.6 years. Observational studies 
have also reported an increased risk for estrogen/progestin combination therapy, 
and a smaller increased risk for estrogen alone therapy, after several years of 
use. In the WHI trial and from observational studies, the excess risk increased 
with duration of use. From observational studies, the risk appeared to return to 
baseline in about five years after stopping treatment. In addition, 
observational studies suggest that the risk of breast cancer was greater, and 
became apparent earlier, with estrogen/progestin combination therapy as compared 
to estrogen alone therapy.</p>
<p>In the CE/MPA substudy, 26% of the women reported prior use of estrogen alone 
and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 
5.6 years during the clinical trial, the overall relative risk of invasive 
breast cancer was 1.24 (95% confidence interval 1.01 â€“ 1.54), and the overall 
absolute risk was 41 vs 33 cases per 10,000 women-years, for CE/MPA compared 
with placebo. Among women who reported prior use of hormone therapy, the 
relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 
vs 25 cases per 10,000 women-years, for CE/MPA compared with placebo. Among 
women who reported no prior use of hormone therapy, the relative risk of 
invasive breast cancer was 1.09, and the absolute risk was 40 vs 36 cases per 
10,000 women-years for CE/MPA compared with placebo. In the same substudy, 
invasive breast cancers were larger and diagnosed at a more advanced stage in 
the CE/MPA group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare 
with no apparent difference between the two groups. Other prognostic factors 
such as histologic subtype, grade and hormone receptor status did not differ 
between the groups.</p>
<p>The use of estrogen plus progestin has been reported to result in an increase 
in abnormal mammograms requiring further evaluation. All women should receive 
yearly breast examinations by a healthcare provider and perform monthly breast 
self-examinations. In addition, mammography examinations should be scheduled 
based on patient age, risk factors, and prior mammogram results.</p>
<a href="http://"></a><a href="http://"></a>3. <span><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span><p>In the Womenâ€™s Health Initiative Memory Study (WHIMS), 4,532 
generally healthy postmenopausal women 65 years of age and older were studied, 
of whom 35% were 70 to 74 years of age and 18% were 75 or older. After an 
average follow-up of 4 years, 40 women being treated with CE/MPA (1.8%, n = 
2,229) and 21 women in the placebo group (0.9%, n = 2,303) received diagnoses of 
probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk for CE/MPA versus placebo was 2.05 (95% 
confidence interval 1.21 â€“ 3.48), and was similar for women with and without 
histories of menopausal hormone use before WHIMS. The absolute risk of probable 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA versus placebo was 45 versus 22 cases per 10,000 
women-years, and the absolute excess risk for CE/MPA was 23 cases per 10,000 
women-years. It is unknown whether these findings apply to younger 
postmenopausal women. (See <span class="Bold"><a href="#section-4">CLINICAL 
PHARMACOLOGY</a></span>, <a href="#section-4.5">Clinical Studies</a> and <span class="Bold"><a href="#section-8">PRECAUTIONS</a></span>, <a href="#section-8.9">Geriatric Use</a>.)</p>
<p>It is unknown whether these findings apply to estrogen alone therapy.</p>
<a href="http://"></a><a href="http://"></a>4. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span><p>A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> 
requiring surgery in postmenopausal women receiving estrogens has been 
reported.</p>
<a href="http://"></a><a href="http://"></a>5. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span><p>Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in 
patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of 
the drug should be stopped and appropriate measures taken to reduce the serum 
calcium level.</p>
<a href="http://"></a><a href="http://"></a>6. Visual abnormalities<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients 
receiving estrogens. Discontinue medication pending examination if there is a 
sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, 
<span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular 
lesions, estrogens should be permanently discontinued.</p>
<a href="http://"></a><a href="http://"></a>7. <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenoma</span><p>Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> appear to be associated with the use of 
oral contraceptives. Although benign, and rare, these may rupture and may cause 
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Such lesions have not yet been 
reported in association with other estrogen or progestagen preparations but 
should be considered in estrogen users having <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, 
<span class="product-label-link" type="condition" conceptid="192438" conceptname="Abdominal mass">abdominal mass</span>, or <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span>. Hepatocellular carcinoma has also been 
reported in women taking estrogen-containing oral contraceptives. The 
relationship of this malignancy to these drugs is not known at this time.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>A. <span>GENERAL</span><a href="http://"></a><a href="http://"></a>1. Addition of a progestin when a woman has not had a 
hysterectomy<p class="First">Studies of the addition of progestin for 10 or more days of a 
cycle of estrogen administration, or daily with estrogen in a continuous 
regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would 
be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a 
precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of 
progestins with estrogens compared to estrogen- alone regimens. These include a 
possible increased risk of breast cancer.</p>
<a href="http://"></a><a href="http://"></a>2. Elevated blood pressure<p>In a small number of case reports, substantial increases in blood 
pressure have been attributed to idiosyncratic reactions to estrogens. In a 
large, randomized, placebo-controlled clinical trial, a generalized effect of 
estrogens on blood pressure was not seen. Blood pressure should be monitored at 
regular intervals with estrogen use.</p>
<a href="http://"></a><a href="http://"></a>3. <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span><p>In patients with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen 
therapy may be associated with elevations of plasma triglycerides leading to 
<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and other complications.</p>
<a href="http://"></a><a href="http://"></a>4. <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired liver function</span> and past history of cholestatic 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span><p>Estrogens may be poorly metabolized in patients with impaired 
liver function. For patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated 
with past estrogen use or with pregnancy, caution should be exercised and in the 
case of recurrence, medication should be discontinued.</p>
<a href="http://"></a><a href="http://"></a>5. <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span><p>Estrogen administration leads to increased thyroid-binding 
globulin (TBG) levels. Patients with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for 
the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the 
normal range. Patients dependent on thyroid hormone replacement therapy who are 
also receiving estrogens may require increased doses of their thyroid 
replacement therapy. These patients should have their thyroid function monitored 
in order to maintain their free thyroid hormone levels in an acceptable 
range.</p>
<a href="http://"></a><a href="http://"></a>6. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span><p>Because estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, 
patients with conditions that might be influenced by this factor, such as a 
cardiac or renal dysfunction, warrant careful observation when estrogens are 
prescribed.</p>
<a href="http://"></a><a href="http://"></a>7. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span><p>Estrogens should be used with caution in individuals with severe 
<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
<a href="http://"></a><a href="http://"></a>8. Ovarian cancer<p>The CE/MPA substudy of WHI reported that estrogen plus progestin 
increased the risk of ovarian cancer. After an average follow-up of 5.6 years, 
the relative risk for ovarian cancer for CE/MPA versus placebo was 1.58 (95% 
confidence interval 0.77 â€“ 3.24) but was not statistically significant. The 
absolute risk for CE/MPA versus placebo was 4.2 versus 2.7 cases per 10,000 
women-years. In some epidemiologic studies, the use of estrogen alone, in 
particular for ten or more years, has been associated with an increased risk of 
ovarian cancer. Other epidemiologic studies have not found these 
associations.</p>
<a href="http://"></a><a href="http://"></a>9. Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span><p><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of 
estrogens. A few cases of malignant transformation of residual endometrial 
implants have been reported in women treated post-hysterectomy with estrogen 
alone therapy. For patients known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> 
post-hysterectomy, the addition of progestin should be considered.</p>
<a href="http://"></a><a href="http://"></a>10. Exacerbation of other conditions<p>Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, 
<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic 
<span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these 
conditions.</p>
<a href="http://"></a><a href="http://"></a>B. PATIENT INFORMATION<p>Physicians are advised to discuss the PATIENT INFORMATION leaflet 
with patients for whom they prescribe Menest.</p>
<a href="http://"></a><a href="http://"></a>C. LABORATORY TESTS<p>Estrogen administration should be initiated at the lowest dose 
approved for the indication and then guided by clinical response, rather than by 
serum hormone levels (e.g., estradiol, FSH).</p>
<a href="http://"></a><a href="http://"></a>D. DRUG/LABORATORY TEST INTERACTIONS<ol>
<li><p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and 
platelet aggregation time; increased platelet count; increased factors II, VII 
antigen, VIII antigen, VIII coagulant activity; IX, X, XII, VII-X complex, 
II-VII-X complex, and betathromboglobulin; decreased levels of antifactor Xa and 
antithrombin III, decreased antithrombin III activity; increased levels of 
fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and 
activity.</p></li>
<li><p class="First">Increased thyroid-binding globulin (TBG) levels leading to 
increased circulating total thyroid hormone levels as measured by protein-bound 
iodine (PBI), T<span class="Sub">4</span> levels (by column or by 
radioimmunoassay) or T<span class="Sub">3</span> levels by radioimmunoassay. 
T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated 
TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> 
concentrations are unaltered. Patients on thyroid replacement therapy may 
require higher doses of thyroid hormone.</p></li>
<li><p class="First">Other binding proteins may be elevated in serum (i.e., 
corticosteroid binding globulin (CBG), <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG)) 
leading to increased total circulating corticosteroids and sex steroids, 
respectively. Free hormone concentrations may be decreased. Other plasma 
proteins may be increased (angiotensinogen/renin substrate, alpha- 
1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</p></li>
<li><p class="First">.Increased plasma HDL and HDL<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased 
triglycerides levels.</p></li>
<li><p class="First">Impaired glucose tolerance. </p></li>
<li><p class="First">Reduced response to metyrapone test.</p></li>
</ol>
<a href="http://"></a><a href="http://"></a>E. CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF 
FERTILITY<p>Long-term continuous administration of estrogen, with and without 
progestin, in women with and without a uterus, has shown an increased risk of 
endometrial cancer, breast cancer, and ovarian cancer. (See <span class="Bold"><a href="#section-2">BOXED WARNINGS</a></span>, <span class="Bold"><a href="#section-7">WARNINGS</a></span> and <span class="Bold"><a href="#section-8">PRECAUTIONS</a></span>.)</p>
<p>Long-term continuous administration of natural and synthetic estrogens in 
certain animal species increases the frequency of carcinomas of the breast, 
uterus, cervix, vagina, testis, and liver.</p>
<a href="http://"></a><a href="http://"></a>F. PREGNANCY<p>Menest should not be used during pregnancy. (See <span class="Bold"><a href="#section-6">CONTRAINDICATIONS</a></span>.)</p>
<a href="http://"></a><a href="http://"></a>G. NURSING MOTHERS<p>Estrogen administration to nursing mothers has been shown to 
decrease the quantity and quality of the milk. Detectable amounts of estrogens 
have been identified in the milk of mothers receiving this drug. Caution should 
be exercised when Menest is administered to a nursing mother.</p>
<a href="http://"></a><a href="http://"></a>H. PEDIATRIC USE<p>Safety and effectiveness in pediatric patients have not been 
established.</p>
<a href="http://"></a><a href="http://"></a>I. <span>GERIATRIC USE</span><p>In the Womenâ€™s Health Initiative Memory Study, including 4,532 
women 65 years of age and older, followed for an average of 4 years, 82% (n = 
3,729) were 65 to 74 while 18% (n = 803) were 75 and over. Most women (80%) had 
no prior hormone therapy use. Women treated with conjugated estrogens plus 
medroxyprogesterone acetate were reported to have a two-fold increase in the 
risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Alzheimerâ€™s disease was the most common 
classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the conjugated estrogens plus 
medroxyprogesterone acetate group and the placebo group. Ninety percent of the 
cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in the 54% of women that were older than 70. 
(See <span class="Bold"><a href="#section-7">WARNINGS</a></span>, <a href="#section-7.3"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>.)</p>
<p>It is unknown whether these findings apply to estrogen alone therapy.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">See <span class="Bold"><a href="#section-2">BOXED 
WARNINGS</a></span>, <span class="Bold"><a href="#section-7">WARNINGS</a></span> 
and <span class="Bold"><a href="#section-8">PRECAUTIONS</a></span>.</p>
<p>The following additional adverse reactions have been reported with estrogens 
and/or progestin therapy.</p>
<a href="http://"></a><a href="http://"></a>1. Genitourinary system<p>Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal withdrawal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; spotting; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, increase in 
size of uterine leiomyomata; <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in 
amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>; ovarian cancer; 
<span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer; premenstrual like syndrome, 
<span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> during and after treatment; <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> like syndrome.</p>
<a href="http://"></a><a href="http://"></a>2. Breasts<p><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; 
<span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer.</p>
<a href="http://"></a><a href="http://"></a>3. Cardiovascular<p>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; 
<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood 
pressure.</p>
<a href="http://"></a><a href="http://"></a>4. Gastrointestinal<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; cholestatic 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; increased incidence of gall bladder disease; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, enlargement 
of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</p>
<a href="http://"></a><a href="http://"></a>5. Skin<p><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span>, that may persist when drug is discontinued; 
<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; 
<span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<a href="http://"></a><a href="http://"></a>6. Eyes<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>; steepening of corneal curvature; 
intolerance to contact lenses.</p>
<a href="http://"></a><a href="http://"></a>7. Central nervous system<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>; <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; 
<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, 
<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</p>
<a href="http://"></a><a href="http://"></a>8. Miscellaneous<p>Increase or decrease in weight; reduced carbohydrate tolerance; 
aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; arthalgias; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; changes in libido; 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>; <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; 
<span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute 
ingestion of large doses of estrogen-containing drug products by young children. 
Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> 
may occur in females.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">When estrogen is prescribed for a postmenopausal woman with a 
uterus, a progestin should also be initiated to reduce the risk of endometrial 
cancer. A woman without a uterus does not need progestin. Use of estrogen, alone 
or in combination with a progestin, should be with the lowest effective dose and 
for the shortest duration consistent with treatment goals and risks for the 
individual woman. Patients should be reevaluated periodically as clinically 
appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is 
still necessary (See <span class="Bold"><a href="#section-2">BOXED 
WARNINGS</a></span> and <span class="Bold"><a href="#section-7">WARNINGS</a></span>.) For women who have a uterus, adequate 
diagnostic measures, such as endometrial sampling, when indicated, should be 
undertaken to rule out malignancy in cases of undiagnosed persistent or 
recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>When estrogen is prescribed for a postmenopausal woman with a 
uterus, a progestin should also be initiated to reduce the risk of endometrial 
cancer. A woman without a uterus does not need progestin. Use of estrogen, alone 
or in combination with a progestin, should be with the lowest effective dose and 
for the shortest duration consistent with treatment goals and risks for the 
individual woman. Patients should be reevaluated periodically as clinically 
appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is 
still necessary (See <span class="Bold"><a href="#section-2">BOXED 
WARNINGS</a></span> and <span class="Bold"><a href="#section-7">WARNINGS</a></span>.) For women who have a uterus, adequate 
diagnostic measures, such as endometrial sampling, when indicated, should be 
undertaken to rule out malignancy in cases of undiagnosed persistent or 
recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>Patients should be started at the lowest dose.</p>
<p>1. Given cyclically for short term use only:</p>
<p>For treatment of moderate to severe vasomotor symptoms, or moderate to severe 
symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p>
<p>Administration should be cyclic (e.g., 3 weeks on and 1 week off).</p>
<p>USUAL DOSAGE RANGES:</p>
<p><span class="Bold">Vasomotor symptoms</span>â€“ 1.25 mg daily. If the patient has 
not menstruated within the last 2 months or more, cyclic administration is 
started arbitrarily. If the patient is menstruating, cyclic administration is 
started on day 5 of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p><span class="Bold">Moderate to severe symptoms of vulvar and vaginal 
<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span></span>â€“ 0.3 mg to 1.25 mg or more daily, depending upon the tissue 
response of the individual patient. Administer cyclically.</p>
<p>2. Given cyclically: Female <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>; female castration; primary ovarian 
failure.</p>
<a href="http://"></a><a href="http://"></a>USUAL DOSAGE RANGES:<p><span class="Bold">Female <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span></span>â€“ 2.5 to 7.5 mg daily, 
in divided doses for 20 days, followed by a rest period of 10 daysâ€™ duration. If 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> does not occur by the end of this period, the same dosage schedule is 
repeated. The number of courses of estrogen therapy necessary to produce 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may vary depending on responsiveness of the endometrium.</p>
<p>If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs before the end of the 10 day period, begin a 20 day 
estrogen-progestin cyclic regimen with Menest (esterified estrogens tablets), 
2.5 to 7.5 mg daily in divided doses, for 20 days. During the last 5 days of 
estrogen therapy, give an oral progestin. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs before this regimen 
is concluded, therapy is discontinued and may be resumed on the fifth day of 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p><span class="Bold">Female castration and <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">primary ovarian failure</span></span>â€” 1.25 
mg daily, cyclically. Adjust dosage upward or downward according to severity of 
symptoms and response of the patient. For maintenance, adjust dosage to lowest 
level that will provide effective control.</p>
<p>3. Given chronically: Inoperable progressing prostatic cancer â€” 1.25 to 2.5 
mg three times daily. The effectiveness of therapy can be judged by phosphatase 
determinations as well as by symptomatic improvement of the patient.</p>
<p>Inoperable progressing breast cancer in appropriately selected men and 
postmenopausal women. (See <span class="Bold"><a href="#section-5">INDICATIONS AND 
USAGE</a></span>) â€“ Suggested dosage is 10 mg three times daily for a period of 
at least 3 months.</p>
<p>Treated patients with an intact uterus should be monitored closely for signs 
of endometrial cancer and appropriate diagnostic measures should be taken to 
rule out malignancy in the event of persistent or recurring abnormal vaginal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>The lowest effective dose of Menest has not been determined.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Tablets: </p>
<p>0.3 mg yellow, film-coated oblong tablet imprinted with M72 <br></p>
<a name="i04f9b19e-28d9-4ba0-8732-a6852ad981b5"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 10<br>
</td>
<td>NDC 54868-6211-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-6211-1<br>
</td>
</tr>
</tbody></table>
<p>0.625 mg orange, film-coated oblong tablet imprinted with M73 <br></p>
<a name="ib7b13a01-0e4d-439a-815d-53167af69fc8"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 10<br>
</td>
<td>NDC 54868-5934-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5934-1<br>
</td>
</tr>
</tbody></table>
<p>1.25 mg green, film-coated oblong tablet imprinted with M74 <br></p>
<a name="i645cba69-979f-4c4e-8ec6-3ba32f4b6822"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 10<br>
</td>
<td>NDC 54868-6212-0<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-6212-1<br>
</td>
</tr>
</tbody></table>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-13"></a><p></p>
<a href="http://"></a>PATIENT INFORMATION<p class="First">(Updated July 9, 2004)</p>
<p><span class="Bold">Menest<span class="Sup">Â®</span></span></p>
<p>(esterified estrogens tablets, USP)</p>
<p>Read this PATIENT INFORMATION before you start taking Menest and read what 
you get each time you refill Menest. There may be new information. This 
information does not take the place of talking to your healthcare provider about 
your medical condition or your treatment.</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">What is the most important information I should 
know about Menest (an estrogen hormone)?</span></p>
<ul><li><p class="First">Estrogens increase the chances of getting cancer of the 
uterus.</p></li></ul>
<p>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are taking 
estrogens. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of 
the uterus (womb). Your healthcare provider should check any unusual vaginal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to find out the cause.</p>
<ul><li><p class="First">Do not use estrogens with or without progestins to prevent heart 
disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.</p></li></ul>
<p>Using estrogens with or without progestins may increase your chances of 
getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, and blood clots. Using estrogens 
with progestins may increase your risk of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. You and your healthcare 
provider should talk regularly about whether you still need treatment with 
Menest.</p>
<a href="http://"></a><a href="http://"></a>What is Menest?<p>Menest is a medicine that contains estrogen hormones.</p>
<a href="http://"></a><a href="http://"></a>What is Menest used for?<p>Menest is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<ul><li><p class="First"><span class="Bold">reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>.</span> 
Estrogens are hormones made by a womanâ€™s ovaries. The ovaries normally stop 
making estrogens when a woman is between 45 to 55 years old. This drop in the 
body estrogen levels causes the â€œchange of lifeâ€? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of 
monthly menstrual periods). Sometimes, both ovaries are removed during an 
operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. This sudden drop in estrogen 
levels causes â€œsurgical <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.â€?</p></li></ul>
<p>When the estrogen levels begin dropping, some women develop very 
uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, 
or sudden strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (â€œhot flashesâ€? or â€œhot flushesâ€?). 
In some women, the symptoms are mild, and they will not need estrogens. In other 
women, symptoms can be more severe. You and your healthcare provider should talk 
regularly about whether you still need treatment with Menest.</p>
<ul>
<li><p class="First"><span class="Bold">treat moderate to severe dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and 
burning in and around the vagina.</span> You and your healthcare provider should 
talk regularly about whether you still need treatment with Menest to control 
these problems. If you use Menest only to treat your dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and 
burning in and around your vagina, talk with your healthcare provider about 
whether a topical vaginal product would be better for you. </p></li>
<li><p class="First"><span class="Bold">treat certain conditions in women before 
<span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> if their ovaries do not make enough estrogen naturally.</span></p></li>
<li><p class="First"><span class="Bold">ease symptoms of certain cancers that have 
spread through the body, in men and women.</span></p></li>
</ul>
<a href="http://"></a><a href="http://"></a>Who should not take Menest?<p>Do not start taking Menest if you:</p>
<ul>
<li><p class="First"><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</span></p></li>
<li><p class="First"><span class="Bold">currently have or have had certain 
cancers.</span> Estrogens may increase the chances of getting certain types of 
cancers, including cancer of the breast or uterus. If you have or had cancer, 
talk with your healthcare provider about whether you should take 
Menest.</p></li>
<li><p class="First"><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year. 
</span></p></li>
<li><p class="First"><span class="Bold">currently have or have had blood clots. 
</span></p></li>
<li><p class="First"><span class="Bold">currently have or have had liver 
problems.</span></p></li>
<li><p class="First"><span class="Bold">are allergic to Menest or any of its 
ingredients.</span> See the end of this leaflet for a list of ingredients in 
Menest. </p></li>
<li><p class="First"><span class="Bold">think you may be pregnant.</span></p></li>
</ul>
<a href="http://"></a><a href="http://"></a>Tell your healthcare provider:<ul>
<li><p class="First"><span class="Bold">if you are breastfeeding.</span> The hormone in 
Menest can pass into your milk. </p></li>
<li><p class="First"><span class="Bold">bout all of your medical problems.</span> Your 
healthcare provider may need to check you more carefully if you have certain 
conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, 
<span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, problems with your heart, liver, thyroid, kidneys, or have 
high calcium levels in your blood. </p></li>
<li><p class="First"><span class="Bold">about all of the medicines you take.</span> This 
includes prescription and nonprescription medicines, vitamins, and herbal 
supplements. Some medicines may affect how Menest works. Menest may also affect 
how your other medicines work. </p></li>
<li><p class="First"><span class="Bold">if you are going to have surgery or will be on 
bed rest.</span> You may need to stop taking estrogens.</p></li>
</ul>
<a href="http://"></a><a href="http://"></a>How should I take Menest?<p>Your healthcare provider will select the lowest appropriate dose 
of Menest, determine how frequently it will be taken, and determine the length 
of time you will be treated, depending on your condition.</p>
<p>For treatment of postmenopausal symptoms, the lowest dose that will control 
symptoms will be selected and used for the shortest amount of time.</p>
<p>In general, you will take Menest for several weeks, skip a week, and then 
begin taking Menest again. Again, your healthcare provider will discuss with you 
the instructions for taking Menest.</p>
<p>If you miss a dose, take it as soon as possible. However, if it is almost 
time for your next dose, skip the missed dose, and go back to your normal 
schedule. Do not take 2 doses at the same time.</p>
<p>Estrogens should be used only as long as needed. You and your healthcare 
provider should talk regularly (for example, every 3 to 6 months) about whether 
you still need treatment with Menest.</p>
<a href="http://"></a><a href="http://"></a>What are the possible side effects of estrogens?<p><span class="Bold">Less common but serious side effects 
include:</span></p>
<ul>
<li><p class="First">Breast cancer </p></li>
<li><p class="First">Cancer of the uterus </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> </p></li>
<li><p class="First">Blood clots </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></p></li>
<li><p class="First">Ovarian cancer</p></li>
</ul>
<a href="http://"></a><a href="http://"></a>These are some of the warning signs of serious side 
effects:<ul>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> </p></li>
<li><p class="First">Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness </p></li>
<li><p class="First">Changes in speech </p></li>
<li><p class="First">Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs </p></li>
<li><p class="First">Changes in vision </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></li>
</ul>
<p>Call your healthcare provider right away if you get any of these 
warning signs, or any other unusual symptom that concerns you.</p>
<a href="http://"></a><a href="http://"></a>Common side effects include:<ul>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span> </p></li>
<li><p class="First">Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting </p></li>
<li><p class="First">Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span></p></li>
</ul>
<a href="http://"></a><a href="http://"></a>Other side effects include:<ul>
<li><p class="First">High blood pressure </p></li>
<li><p class="First">Liver problems </p></li>
<li><p class="First">High blood sugar </p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> </p></li>
<li><p class="First">Enlargement of benign tumors of the uterus (â€œfibroidsâ€?) </p></li>
<li><p class="First">Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></p></li>
</ul>
<p>These are not all the possible side effects of Menest. For more 
information, ask your healthcare provider or pharmacist.</p>
<a href="http://"></a><a href="http://"></a>What can I do to lower my chances of a serious side 
effect with Menest?<ul>
<li><p class="First">Talk with your healthcare provider regularly about whether you 
should continue taking Menest. If you have a uterus, talk to your healthcare 
provider about whether the addition of a progestin is right for you. </p></li>
<li><p class="First">See your healthcare provider right away if you get vaginal 
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while taking Menest. </p></li>
<li><p class="First">Have a breast exam and mammogram (breast X-ray) every year unless 
your healthcare provider tells you something else. If members of your family 
have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal 
mammogram, you may need to have breast exams more often. </p></li>
<li><p class="First">If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the 
blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher 
chances for getting heart disease. Ask your healthcare provider for ways to 
lower your chances for getting heart disease.</p></li>
</ul>
<a href="http://"></a><a href="http://"></a>General information about safe and effective use of 
Menest.<p>Medicines are sometimes prescribed for conditions that are not 
mentioned in patient information leaflets. Do not take Menest for conditions for 
which it was not prescribed. Do not give Menest to other people, even if they 
have the same symptoms you have. It may harm them. <span class="Bold">Keep Menest 
out of the reach of children.</span></p>
<p>This leaflet provides a summary of the most important information about 
Menest. If you would like more information, talk with your healthcare provider 
or pharmacist. You can ask for more information about Menest that is written for 
health professionals. You can get more information by calling the toll free 
number 1-800-776- 3637, and select option 5.</p>
<a href="http://"></a><a href="http://"></a>What are the ingredients in Menest?<p>Menest is a mixture of esterified estrogens that are of the type 
excreted by pregnant mares. Menest also contains ethyl cellulose, fragrances, 
hydroxypropyl cellulose, hypromellose 2910, lactose, magnesium stearate, 
methylcellulose, polyethylene glycol, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, shellac, starch, 
stearic acid, titanium dioxide, and vanillin. The tablets come in different 
strengths; the color ingredients for each strength are:</p>
<p>0.3 mg Tablet: FD&amp;C Yellow No. 6, D&amp;C Yellow No. 10. </p>
<p>0.625 mg Tablet: FD&amp;C Yellow No. 6, D&amp;C Yellow No. 10. </p>
<p>1.25 mg Tablet: FD&amp;C Yellow No. 6, D&amp;C Yellow No. 10, and FD&amp;C 
Blue No. 1.</p>
<p>2.5 mg Tablet: D&amp;C Red No. 30.</p>
<p><span class="Bold">Rx only.</span></p>
<p>Prescribing Information as of July 9, 2004.</p>
<p>Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620 </p>
<p>(A wholly owned subsidiary of King Pharmaceuticals, Inc.) </p>
<p>Manufactured by: <br>King Pharmaceuticals, Inc., Bristol, TN 37620</p>
<br><br><span class="Bold">Relabeling and Repackaging by:<br></span>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â  74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Menest (estrogens, esterified) Tablets</p>
<p>0.3 mg</p>
<div class="Figure"><img alt="image of 0.3 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efb195b9-b995-48f3-a4cb-b7e09d56350e&amp;name=6211.jpg"></div>
<p>0.625 mg</p>
<p><img alt="image of 0.625 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efb195b9-b995-48f3-a4cb-b7e09d56350e&amp;name=5934.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First">1.25 mg</p>
<p><img alt="image of 1.25 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efb195b9-b995-48f3-a4cb-b7e09d56350e&amp;name=6212.jpg"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MENESTÂ 		
					</strong><br><span class="contentTableReg">estrogens, esterified tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6211(NDC:61570-072-01)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, ESTERIFIED</strong> (ESTROGENS, ESTERIFIED) </td>
<td class="formItem">ESTROGENS, ESTERIFIED</td>
<td class="formItem">0.3Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>VANILLIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M72</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6211-0</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-6211-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA084951</td>
<td class="formItem">12/09/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MENESTÂ 		
					</strong><br><span class="contentTableReg">estrogens, esterified tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5934(NDC:61570-073-01)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, ESTERIFIED</strong> (ESTROGENS, ESTERIFIED) </td>
<td class="formItem">ESTROGENS, ESTERIFIED</td>
<td class="formItem">0.625Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>VANILLIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M73</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5934-0</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5934-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA084948</td>
<td class="formItem">09/05/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MENESTÂ 		
					</strong><br><span class="contentTableReg">estrogens, esterified tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6212(NDC:61570-074-01)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, ESTERIFIED</strong> (ESTROGENS, ESTERIFIED) </td>
<td class="formItem">ESTROGENS, ESTERIFIED</td>
<td class="formItem">1.25 Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>VANILLIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M74</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6212-0</td>
<td class="formItem">10  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-6212-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA084950</td>
<td class="formItem">12/16/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b02b798f-01b7-491e-8802-11057828e6f6</div>
<div>Set id: efb195b9-b995-48f3-a4cb-b7e09d56350e</div>
<div>Version: 2</div>
<div>Effective Time: 20101210</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
